Tumor Treating Fields (TTF) Therapy

This policy covers Tumor Treating Fields (TTF) therapy (Optune®) for adults (≥18 years) with supratentorial glioblastoma multiforme—used as an adjunct to maintenance temozolomide after maximal resection and radiation for newly diagnosed GBM or as monotherapy for recurrent GBM—for patients with Karnofsky Performance Status ≥60%, with treatment authorized only until disease progression. Coverage requires adherence to the FDA device label (including shaved head), excludes infratentorial tumors, patients <18 or KPS <60, those unable/unwilling to comply or with contraindications (e.g., implanted electronic devices or skull defects), and is subject to the member’s benefit plan limits.

"TTF therapy as an adjunct to standard maintenance temozolomide for newly diagnosed glioblastoma multiforme (GBM) following maximal debulking surgery and completion of radiation therapy with concomi..."